LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Начало・Списък с акции・Ligand Pharmaceuticals Inc

Ligand Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

235.49 1.33

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

229.94

Максимум

240.55

Ключови измерители
By Trading Economics
Приходи	-58M -13M
Продажби	-7.9M 52M
P/E Средно за сектора	29.958 49.888
EPS	-0.67
Марж на печалбата	-25.801
Служители	47
EBITDA	-49M 17M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+15.53% upside

Дивиденти
By Dow Jones
Следващи печалби	6.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	1.8B 4.6B
Предишно отваряне	234.16
Предишно затваряне	235.49

Настроения в новините

By Acuity

50%

155 / 344 Класиране в Healthcare

Ligand Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

4.06.2026 г., 21:51 ч. UTC

Значими двигатели на пазара

Merlin Shares Rally After Defense Department's Design Review Wraps

4.06.2026 г., 23:46 ч. UTC

Пазарно говорене

U.S. Jobs Data May Offer Bullish Catalyst for Dollar Vs. Yen -- Market Talk

4.06.2026 г., 23:44 ч. UTC

Пазарно говорене

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

4.06.2026 г., 23:42 ч. UTC

Придобивния, сливания и поглъщания

Energy Resources of Australia: Court to Decide on Rio Tinto Compulsory Acquisition Request

4.06.2026 г., 23:41 ч. UTC

Придобивния, сливания и поглъщания

Energy Resources of Australia to Enter Trading Halt

4.06.2026 г., 23:34 ч. UTC

Пазарно говорене

Oil Edges Lower Amid Mixed Middle East Developments -- Market Talk

4.06.2026 г., 23:31 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

4.06.2026 г., 23:31 ч. UTC

Пазарно говорене

Mercury NZ Loses Bull Despite Sector Earnings Powering Up -- Market Talk

4.06.2026 г., 23:31 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

4.06.2026 г., 23:08 ч. UTC

Пазарно говорене

Narrowing Rate Differentials Make Australian Dollar Less Attractive Versus USD -- Market Talk

4.06.2026 г., 22:41 ч. UTC

Пазарно говорене

Australia Shares Set to Rise at the Open -- Market Talk

4.06.2026 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

4.06.2026 г., 20:44 ч. UTC

Придобивния, сливания и поглъщания

RTX Stock Rises After Catching an Upgrade. Why This Analyst Is Bullish. -- Barrons.com

4.06.2026 г., 20:16 ч. UTC

Пазарно говорене

Mexican Demand Indicators Show Signs of Life -- Market Talk

4.06.2026 г., 20:15 ч. UTC

Придобивния, сливания и поглъщания

Gilead Sciences And Lakefront Complete Acquisition Of Ouro Medicines To Further Expand Inflammation Pipeline >GILD

4.06.2026 г., 19:46 ч. UTC

Пазарно говорене

Treasury Yields Decline Ahead of U.S. Payrolls -- Market Talk

4.06.2026 г., 19:38 ч. UTC

Пазарно говорене

Oil Futures Retreat After 3-Session Winning Streak -- Market Talk

4.06.2026 г., 19:30 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Rise on Weather, Storage Data -- Market Talk

4.06.2026 г., 18:47 ч. UTC

Придобивния, сливания и поглъщания

Google Stock Attracts Cathie Wood's ARK and Berkshire Hathaway. That's Rare. -- Barrons.com

4.06.2026 г., 18:38 ч. UTC

Печалби

Money Quote: Tech Weakness in Context -- WSJ

4.06.2026 г., 18:24 ч. UTC

Печалби

Quantinuum, Broadcom, UnitedHealth, and More Stocks That Explain Today's Market -- Barrons.com

4.06.2026 г., 17:09 ч. UTC

Пазарно говорене

Retest of $55k Seen Possible for Bitcoin -- Market Talk

4.06.2026 г., 16:58 ч. UTC

Печалби

Broadcom, UnitedHealth, Blackstone, Ciena, and More Stocks That Explain Today's Market -- Barrons.com

4.06.2026 г., 16:46 ч. UTC

Пазарно говорене

Strategy BTC Sale Continues to Weigh on Prices -- Market Talk

4.06.2026 г., 16:38 ч. UTC

Печалби

UnitedHealth Stock Rises. Why the Health Insurer Is Leading the Dow to Sharp Gains. -- Barrons.com

4.06.2026 г., 16:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

4.06.2026 г., 16:20 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

4.06.2026 г., 16:13 ч. UTC

Пазарно говорене

On Again, Off Again Deals Keep Oil Market on Edge -- Market Talk

4.06.2026 г., 16:11 ч. UTC

Пазарно говорене

Copper Market Is Awaiting Key U.S. Tariff Decision -- Market Talk

4.06.2026 г., 15:56 ч. UTC

Пазарно говорене

Copper Rises Amid Hormuz Disruptions, U.S. Stockpiling -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Ligand Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

15.53% нагоре

12-месечна прогноза

Среден 270.8 USD 15.53%

Висок 289 USD

Нисък 255 USD

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за Ligand Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

6 ratings

Купи

Задържане

Продай

Според 6 анализатори, дали борсови рейтинги на Ligand Pharmaceuticals Inc през последните 3 месеца.

Настроение

By Acuity

155 / 344 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Ligand Pharmaceuticals Inc

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.